InPharmX Inc., DBA University Learning Systems Phone: 1-800-940-5860 Email: info@universitylearning.com
Professional learning online at a desk
← All on demand pharmacology CE/CME

On demand pharmacology CE/CME

Current Treatment Strategies

FormatSelf-paced onlineRecordedDecember 9–11, 2025AccessAvailable now

About this course

Learn at your own pace.

  • 2025-12-09 Statins and Beyond: Innovations in Dyslipidemia Therapy and Cardiovascular Risk Reduction
  • 2025-12-10 Honing in on Herbal Remedies, Overcoming Obesity, and Drug Therapy Jeopardy
  • 2025-12-11 Pressure Points: Advancing Hypertension Care and Cardiovascular Risk Reduction through Guidelines, Risk Reduction, and Emerging Therapies
  • Total hours: 15
  • Recorded Live in Las Vegas on December 9-11 2025

Educational information

Designed for meaningful, practical learning.

Sessions

Session
2025-12-09 Statins and Beyond: Innovations in Dyslipidemia Therapy and Cardiovascular Risk Reduction

Tuesday, December 9, 2025

Speaker: Dr. Joseph Saseen Credit hours: 5 ACPE UAN: 0741-0000-25-026-H01-P

Learning objectives
  1. Apply recommendations from the American College of Cardiology/American Heart Association guidelines for treatment of patients with hypercholesterolemia, chronic coronary disease, and peripheral arterial disease.,
  2. Apply the treatment approaches recommended in the 2018 ACC-AHA cholesterol guideline to patients with hypercholesterolemia.
  3. Interpret recommendations from the ACC Expert Consensus Decision Pathway for nonstatins and treatment of hypertriglyceridemia.
  4. Interpret the evidence and role in therapy of nonstatin medications in the treatment of hypercholesterolemia.
  5. Demonstrate the evidence and guideline recommendations supporting the use of antiplatelet and antithrombotic therapy for secondary prevention patients.
  6. Evaluate evidence-based drug therapy recommendations for the management of patients with chronic coronary disease and peripheral arterial disease.
  7. Evaluate the role of colchicine in the prevention of CV events.
  8. Create treatment plans that reduce the risk of cardiovascular disease.
2025-12-10 Honing in on Herbal Remedies, Overcoming Obesity, and Drug Therapy Jeopardy

Thursday, December 11, 2025

Speaker: Dr. Christopher M. Bland Credit hours: 5 ACPE UAN: 0741-0000-25-030-H01-P

Learning objectives
  1. Honing in on Herbal Remedies: Review of Commonly Used Agents
  2. Describe the FDA regulatory framework for determining safety, efficacy, and labeling of herbal products.
  3. Identify common herbal supplements and their potential therapeutic uses, as well as their associated adverse effects and various interactions with prescription or other over-the-counter medications.
  4. Evaluate the safety and effectiveness of herbal supplements using evidence-based resources and patient-specific factors within example cases
  5. Overcoming Obesity: Update on Current and Future Pharmacotherapy Options
  6. Describe appropriate patients who may benefit from obesity pharmacotherapy
  7. Evaluate common obesity medications with potential therapeutic uses as well as common and severe adverse reactions
  8. Identify potential future obesity medication therapies that may offer advantages over current FDA-approved agents
  9. Drug Therapy Jeopardy
  10. Identify key laboratory values and parameters for monitoring drug therapy.
  11. Describe key characteristics of common drug therapies.
  12. Identify clinical pearls from various pharmacotherapy therapies
2025-12-11 Pressure Points: Advancing Hypertension Care and Cardiovascular Risk Reduction through Guidelines, Risk Reduction, and Emerging Therapies

Wednesday, December 10, 2025

Speaker: Dr. Joseph Saseen Credit hours: 5 ACPE UAN: 0741-0000-25-027-H01-P

Learning objectives
  1. At the completion of this activity, the participant will be able to:
  2. Explain recommendations from the American College of Cardiology/American Heart Association guidelines for treatment of patients with hypertension.
  3. Review lifestyle modifications that are recommended for the treatment and prevention of cardiovascular disease . 3
  4. Summarize how future cardiovascular risk is estimated in primary prevention patients using the Pooled Cohort Equations and PREVENT calculator.
  5. Formulate a care plan for patients with resistant hypertension based on the 2018 American Heart Association scientific statement.
  6. Illustrate emerging pharmacotherapies for the treatment of hypertension.
  7. Analyze guideline recommendations supporting the use of antiplatelet therapy for primary prevention patients.
  8. Examine the evidence-based CV risk reduction benefits of medications used to treat overweight and obese patients.
  9. Create treatment plans that reduce the risk of cardiovascular disease.

Faculty

Portrait of Dr. Joseph Saseen, ULS faculty member

Dr. Joseph Saseen, PharmD, FASHP, FCCP, BCPS, BCACP

Associate Dean for Clinical Affairs and Professor · University of Colorado Skaggs School of Pharmacy

A nationally recognized ambulatory-care and cardiovascular-risk-reduction educator with nearly 200 peer-reviewed publications and book chapters.

Professional profile ↗
Portrait of Dr. Christopher M. Bland, ULS faculty member

Dr. Christopher M. Bland, PharmD, FCCP

Clinical Professor · University of Georgia College of Pharmacy

A clinical pharmacy educator and co-founder of Southeastern Research Group Endeavor and TeachMePharm, with a focus on practical infectious-disease pharmacotherapy.

Professional profile ↗

Accreditation

Target audience

Pharmacists, Nurse Practitioners, Physicians, Physician Assistants, Nurses

PHARMACISTS

  • University Learning Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. 
  • These programs are accredited for all pharmacists.
  • This course provides 15 hours or 1.5 CEUs.
  • Credit for this course expires on December 11, 2028.

PHYSICIANS

The American Academy of Family Physicians (AAFP) has reviewed Current Treatment Strategies and deemed it acceptable for up to 15 Live AAFP Prescribed credit(s). Term of Approval is from December 9, 2025 to December 11, 2025 Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 credit(s) toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

American Osteopathic Association (AOA).‍ ‍ Continuing medical education (CME) activities approved for American Academy of Family Physicians (AAFP) credit are recognized by the American Osteopathic Association (AOA) as equivalent to AOA Category 2 credit. 

NURSES

  • This course provides 15 hours (1.5 CEU)
  • University Learning Systems is approved by the California Board of Registered Nursing, Provider Number CEP 11409, and CE Broker Tracking #50-11357:
  • University Learning Systems is approved by CE Broker for Florida, Georgia, Arkansas, District of Columbia, Georgia, New Mexico, and West Virginia, Boards of Nursing. 
  • The same hours submitted to renew NP certification may be submitted to a State Board of Nursing for re-licensure.

OTHER PROFESSIONS

  • CONSULTANT PHARMACISTS: Some consultant pharmacist boards accept University Learning Systems courses for recertification either as is or with board approval. Please contact your board regarding course approval and ULS with any questions.

  • CANADIAN PHARMACISTS:Canadian Council on Continuing Education in Pharmacy (CCCEP)accepts courses accredited by the Accreditation Council for Pharmacy Education (ACPE). 

  • CANADIAN PHYSICIANS: Members of the College of Family Physicians of Canada are eligible to receive up to 15 MAINPRO-M1 credits for participation in this activity due to reciprocal agreement with the American Academy of Family Physicians

  • Other healthcare professionals should confirm acceptance and reporting requirements with their licensing or certification board

Requirements and reporting

  • University Learning Systems reports pharmacy credit through CPE Monitor using the participant’s eNABPID number and date of birth.
  • University Learning Systems is approved by CE Broker, for pharmacy, medicine and nursing for participating states,  Tracking #50-11357. Participant's state license number is required for reporting.
  • Credit is based on completed evaluations for registered sessions. 
  • Credit is awarded per session; partial session credit is not available, and breaks are excluded.
  • Other eligible participants receive an applicable statement of credit after completing the required documentation.

Review complete ULS accreditation statements →

Course fees

DescriptionPrice
Default 15 Hours$250